M. Hailey-Hailey: hSPCA1 Expression and Skin Structure Upon Laser Therapy

NCT03849989 | Completed

• 1 other identifier: 64815
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

Hailey-Hailey disease is a genetic acantholytic dermatosis characterized by continuous erosion of the skin that results in a burning, painful sensation and restricts the patient in daily life. This disorder results from a genetic defect in a calcium pump, i.e. the hSPCA1 pump. Calcium pumps are crucial for the processing of cell-cell adhesion proteins such as E-cadherin, part of desmosomes, the major glue between keratinocytes in skin epidermis. Today therapy is mainly focussed on symptom relief and prevention of secondary infection. Ablative laser therapy is known to result in a speedy healing of the affected skin site within 2 weeks following laser therapy. The fact that the treated skin site remains clear from this acantholytic disorder in the months/years following ablation, regardless the existence of a germline mutation, suggests that an epigenetic modification occurs in the process of wound healing. Objective: to (1) study the expression of hSPCA1 in keratinocytes before and after laser therapy and (2) verify the loss of acantholysis by immunohistochemistry and electron microscopy of cell-cell adhesions before and after laser therapy

Conditions

Hailey Hailey Disease

Outcome Measures

Primary Outcomes (2)

• hSPCA1 expression

  Expression of the hSPCA1 calcium pump in keratinocytes before ablative treatment

  Assessed at time point 0 weeks

• hSPCA1 expression

  Expression of the hSPCA1 calcium pump in keratinocytes after ablative treatment

  Assessed 6 weeks after ablative treatment

Secondary Outcomes (2)

• Ultrastructure of the skin before and after ablative treatment by electron microscopy and comparison to clinically uninvolved skin and skin of patients without Hailey-Hailey disease.

  At 0 weeks and 6 weeks after ablative therapy

• Expression and localization of desmosomal proteins before and after ablative therapy by immunofluorescence.

  At 0 weeks and 6 weeks after ablative therapy

Study Arms (1)

Hailey-Hailey disease

EXPERIMENTAL

Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy. Skin biopsy specimens will be taken before and after lasertherapy at three time points. Before treatment: Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction Immediately after treatment of the treated area: 2 mm punch for histopathology Six weeks after treatment: Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy 2mm punch biopsy of clinically uninvolved skin of the upper arm for electron microscopy Patients without Hailey-Hailey disease: 2mm punch biopsy of skin of the upper arm for electron microscopy

Procedure: Skin biopsy

Interventions

Skin biopsy PROCEDURE

Skin biopsy: Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+. Steps: * Skin desinfection with chlorhexidine digluconate 1% solution * Local anaesthesia with lidocaine hydrochloride 1% * Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical) * Biopsy specimens are retrieved with sterile pincer and cut with sterile blade * Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0). * Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks * In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage.

Hailey-Hailey disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Hailey-Hailey patients
• Clinically diagnosed M. Hailey-Hailey as confirmed by histopathology and/or genetic analysis.
• Indication for ablative laser therapy
• \>18 years old
• Informed consent
• Patients without Hailey-Hailey disease
• \>18 years old
• Clinically no symptoms of M. Hailey-Hailey
• Informed consent

You may not qualify if:

• \<18 years old
• Treatment with tetracyclines, topical hormones or oral retinoids within the last 30 days preceding participation
• Lack of informed consent

Sponsors & Collaborators

• Maastricht University Medical Center: lead

Study Sites (1)

Maastricht University Medical Center

Maastricht, Limburg, 6202 AZ, Netherlands

Location

Related Links

• Hailey-Hailey disease and tight junctions: Claudins 1 and 4 are regulated by ATP2C1 gene encoding Ca(2+) /Mn(2+) ATPase SPCA1 in cultured keratinocytes.
• Carbon dioxide laser treatment in Hailey-Hailey disease: a series of 8 patients.
• The coexistence of Darier's disease and Hailey-Hailey disease symptoms.
• Efficacy of erbium:YAG laser ablation in Darier disease and Hailey-Hailey disease.
• Carbon dioxide laser treatment for Hailey-Hailey disease: a retrospective chart review with patient-reported outcomes.
• Laser therapy for the treatment of Hailey-Hailey disease: a systematic review with focus on carbon dioxide laser resurfacing.

MeSH Terms

Conditions

Pemphigus, Benign Familial

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Vesiculobullous

Study Officials

• Valerie Verstraeten, MD PhD

  Maastricht University Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 19, 2019
• First Posted: February 21, 2019
• Study Start: December 21, 2018
• Primary Completion: March 15, 2024
• Study Completion: March 15, 2024
• Last Updated: March 20, 2024

Record last verified: 2019-02

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)